Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoi ...